CVRx

Minneapolis, United States Founded: 2001 • Age: 25 yrs Listed
Implantable technology for hypertension and heart failure is developed.

About CVRx

CVRx is a publicly listed company based in Minneapolis (United States) founded in 2001. Implantable technology for hypertension and heart failure is developed. CVRx has raised $368.5 million across 9 funding rounds from investors including SVB, DaVita and Oxford Finance. The company has 206 employees. CVRx offers products and services including Barostim. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Therapeutic Devices. Its legal entity is CVRX, INC. Its competitors include Adona Medical, Element Science and Ancora Heart; 3 of its 3 listed competitors have raised funding.

Company details

CVRx is a developer of implantable technology for hypertension and heart failure. The product Barostim neo is implanted under the skin, similar to a pacemaker. It then sends signals to the bodys cardiovascular regulators to improve cardiac and vascular function by restoring sympathovagal balance through activation of the afferent and efferent pathways of the autonomic nervous system. The product is CE marked and approved for sale in Europe for both indications.

Key Metrics
  • Annual Revenue
    $56.65 M (USD)
    10.45
    as on Dec 31, 2025
  • Net Profit
    -$53.31 M (USD)
    11.1
    as on Dec 31, 2025
  • EBITDA
    -$50.51 M (USD)
    14.2
    as on Dec 31, 2025
  • Total Equity Funding
    $368.5M (USD)

    in 9 rounds

  • Latest Funding Round
    $50M (USD), Series F

    Jul 2020

  • Investors
    SVB

    & 20 more

  • Employee Count
    206

Products & Services of CVRx

CVRx offers a comprehensive portfolio of products and services, including Barostim.

Barostim
Implantable Device

Delivers electrical pulses to improve heart failure symptoms and quality of life.

Apps and channels of CVRx

its YouTube channel Barostim for Treatment of Heart Failure Symptoms has 60.4K subscribers and 30 videos.

Barostim for Treatment of Heart Failure Symptoms
YouTube 60.4K subscribers 30 videos Science & Technology
Open channel

Videos from CVRx

The most watched videos on CVRx's YouTube channel, Barostim for Treatment of Heart Failure Symptoms (60.4K subscribers). Click a video to play it here.

Barostim Device for Heart Failure - Johnny's Story
676.6K views
Barostim Device for Heart failure - Fred's story
79.3K views
Barostim Therapy - Kevie's Short Story
67.3K views
Barostim Therapy - Patients Short Stories
14.2K views

More on Barostim for Treatment of Heart Failure Symptoms.

Funding Insights of CVRx

CVRx has successfully raised a total of $368.5M across 9 strategic funding rounds. The most recent funding activity was a Series F round of $50 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $368.5M
  • Total Rounds 9
  • Last Round Series F β€” $50M
  • First Round $22M

    (Jul 2003)

  • Investors Count 21

All 9 funding rounds of CVRx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

Valuation history

21 investors in total: 21 institutional.

Investors in CVRx

CVRx has secured backing from 21 investors, including institutional and venture fund investors. Prominent investors backing the company include SVB, DaVita and Oxford Finance.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Venture capital investments are offered to startups by NEA.
nea.comMenlo Park, United States
Ysios Capital is recognized as a leading life sciences investor.
ysioscapital.comBarcelona, Spain
Private equity and venture captial firm focused on healthcare sectors
gildehealthcare.comCambridge, United States
Stage-agnostic investments in US life sciences are pursued.
actionpotentialvc.comPalo Alto, United States
Venture debt firm focused on the life sciences sector
2002oxfordfinance.comAlexandria, United States
Venture capital firm backed by Johnson & Johnson
jnjinnovation.com/jjdcCambridge, United States
Sightline Partners is focused on secondary buyouts and joint ventures in healthcare.
2004sightlinepartners.comBloomington, United States
Early-stage investing in IT and healthcare ventures.
interwest.com
Healthcare sector private equity investments are managed by the firm.
1991frazierhealthcare.comSeattle, United States
Venture capital is invested in US life sciences companies.
kearnyvp.comSan Francisco, United States
Premium access

Investor details for CVRx

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of CVRx

64 people are tracked at CVRx (13 in leadership, 6 in board & advisors, 45 in team); the tracked headcount is 206.

NameRoleGroup
Al Crouse
VP, Quality Assurance & Regulatory AffairsLeadership
Jared Oasheim
CFOLeadership
Paul Verrastro
Chief Marketing & Strategy OfficerLeadership
Thomas Hengsteler
VP, European Sales & MarketingLeadership
Dean Bruhn-Ding
VP, Regulatory Affairs & Quality AssuranceLeadership
Paul Pignato
VP of OperationsLeadership
Jonelle Burnham
VP & General CounselLeadership
Jon Kilzer
Director Of Financial Planning And AnalysisLeadership
Matthew Dagley
Director Of Marketing And DevelopmentLeadership
Parker Knight
Regional Sales Director - SoutheastLeadership
Joe Tsokanos
Senior Director Of Commercial Excellence And AccelerationLeadership
Michael Brown
Sales DirectorLeadership
Seth Wilks
Director Of Clinical ScienceLeadership
Kevin Hykes
DirectorBoard & advisors
Martha Shadan
DirectorBoard & advisors
Kirk Nielsen
DirectorBoard & advisors
Ali Behbahani
DirectorBoard & advisors
Joseph Slattery
DirectorBoard & advisors
Mudit K. Jain
Board Of Directors, Chair Compensation Committee, Nom & Gov CommitteeBoard & advisors
Ryan Billups
Senior Clinical Sales RepresentativeTeam

44 more people are available in the full profile.

Premium access

Complete people profiles for CVRx

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of CVRx

CVRx is a publicly listed company on the NASDAQ with ticker symbol CVRX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date30 Jun 2021
  • Listed onNASDAQ: CVRX
  • Listed entityCVRx, Inc.
  • Exchange sectorHealth technology
  • ISINUS1266381052
  • Share price$1.36 (-8.11% on the day) · 2026-10-13
  • Market capitalisation$36.2M
  • EPS (diluted, trailing year)$-1.97
  • Volume (last session)490,504

Financials of CVRx

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025$56.6M-$53.3M-$50.5M
2024$51.3M-$60.0M-$58.9M
2023$39.3M-$41.2M-$42.6M
2022$22.5M-$41.4M-$42.1M
2021$13.0M-$43.1M-$25.8M
Premium access

Detailed financial statements for CVRx

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of CVRx

4 dated milestones of CVRx across 20 years, from founding to its latest funding, stage changes and deals.

  1. Founded CVRx is founded.
  2. Funding First funding round of $22.0M.
  3. Funding Latest funding round, Series F, of $50.0M.
  4. IPO Lists on the stock exchange (IPO).

Competitors of CVRx

CVRx has 3 listed competitors in our database, 3 of them funded. They include Adona Medical, Element Science and Ancora Heart.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
adonamed.com2017Campbell, United States$71M
Medical devices for heart failure management are developed.
elementscience.com2013San Francisco, United States$192.6M
Wearable patch defibrillators are developed for sudden cardiac arrest treatment.
ancoraheart.com2001San Francisco, United States$151.26M89
Minimally invasive ventriculoplasty system for heart failure and FMR
Premium access

Detailed competitors of CVRx

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of CVRx

The website of CVRx (cvrx.com) receives about 3.5K visits a month.

  • Monthly visits
    3.5K

    ▲ 6.7% vs previous month

Similar websites

Websites whose visitors overlap most with CVRx. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
hfsa.org
hfsa.org
100%
#808,435–
cardiovascularbusiness.com
cardiovascularbusiness.com
96%
#301,603–
myokardia.com
70%
View details
atacand-us.com
atacand-us.com
62%
–
heartfailure.org
heartfailure.org
62%
–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 7 similar websites and full traffic analytics for CVRx

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 7 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Cardiac and Vascular Disorders

3 companies that operate in the same segment as CVRx (Cardiac and Vascular Disorders) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Gene-editing therapies for coronary artery disease are developed.
2018Cambridge, Massachusetts, United StatesUSD 215.5 M255
Cardiac monitoring devices and applications are provided for heart health.
2010Mountain View, California, United StatesUSD 114.38 MUSD 6.18 M67
Therapies for lowering low-density lipoprotein cholesterol levels are developed.
1998Ann Arbor, Michigan, United StatesUSD 129.7 MUSD 332.31 M304
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Cvrx

Premium access

Complete news archive for CVRx

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about CVRx

CVRx was founded in 2001 and raised its 1st funding round 2 years after it was founded.

CVRx is headquartered in Minneapolis, United States. It is registered at Minneapolis, Minnesota, United States.

CVRx is a funded company, having raised a total of $368.5M across 9 funding rounds to date. The company's 1st funding round was a Series B of $22M, raised on Jul 2003.

CVRx has 206 employees.

Annual revenue of CVRx is $56.65M as on Dec 31, 2025.

CVRx is a developer of implantable technology for hypertension and heart failure. The product Barostim neo is implanted under the skin, similar to a pacemaker. It then sends signals to the bodys cardiovascular regulators to improve cardiac and vascular function by restoring sympathovagal balance through activation of the afferent and efferent pathways of the autonomic nervous system. The product is CE marked and approved for sale in Europe for both indications.

CVRx's top competitors include Adona Medical, Element Science and Ancora Heart.

CVRx offers Barostim.

Yes, CVRx is publicly traded on NASDAQ under the ticker symbol CVRX.

CVRx has 21 investors. Key investors include SVB, DaVita, Oxford Finance, Frazier Healthcare Partners, and Piper Jaffray.

CVRx operates through Cvrx, Inc..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available